Most Recent
Directed Electronics appeals partial loss in case over ‘reprehensible’ trade secrets theft
Intellectual Property 2023-04-14 11:38 pm By Christine Caulfield

Car electronics company Directed Electronics has challenged a ruling that partially dismissed its case over the alleged misappropriation of trade secrets by a former manager, who was found to have pocketed $3.6 million in commissions through a secret agreement with rival Hanhwa.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Directed Electronics wins suit over ‘reprehensible’ theft by ex-manager
Intellectual Property 2022-11-25 10:42 pm By Sam Matthews

Automotive electronics company Directed Electronics has largely prevailed in a five-year-old lawsuit alleging a former manager misappropriated company information and reaped $3.6 million in commissions through a secret side agreement with South Korean giant Hanhwa.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Celgene drops patent suit against Dr Reddy’s over Revlimid generic
Intellectual Property 2022-02-25 11:15 am By Cat Fredenburgh

Bristol-Myers Squibb unit Celgene has dropped a lawsuit accusing Indian generics company Dr Reddy’s Laboraties of threatening to infringe its patent for Revlimid with the planned launch of a generic version of the blockbuster cancer drug in Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Dr Reddy’s must warn Celgene of plans to sell generic blockbuster cancer drug
Intellectual Property 2021-12-07 2:55 pm By Cindy Cameronne

Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Ono Pharmaceutical faces grilling by Full Court in patent extension appeal
Intellectual Property 2021-11-04 9:20 pm By Miklos Bolza

Drug company Ono Pharmaceutical has faced tough questioning by an appeals court in a fight with IP Australia over a decision that secured it a patent extension for its cancer immunotherapy drug Opdivo.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?